Mr. Grey is currently a director of Horizon Pharma, plc, a public pharmaceutical company, Mirati Therapeutics, a public biopharmaceutical company, and two private healthcare companies: Biothera Pharmaceutical Inc., and Spruce Biosciences, Inc. where he serves as Executive Chairman. The investigation on behalf of current long term investors in NASDAQ: BMRN stocks, concerns whether certain BioMarin Pharmaceutical Inc. directors are liable in connection with the allegations made in that lawsuit. BioMarin was also the first company to provide therapeutics f… Comparing BioMarin Pharmaceutical Inc.'s CEO Compensation With the industry . BioMarin is a world leader in developing and commercializing innovative biopharmaceuticals for rare diseases driven by genetic causes. For more information, please see our, Valoctocogene Roxaparvovec for Severe Hemophilia A, PALYNZIQ® (pegvaliase-pqpz) Injection for PKU, Kuvan® (sapropterin dihydrochloride) for PKU, Brineura® (cerliponase alfa) for CLN2 Disease, Vimizim® (elosulfase alfa) for Morquio A Syndrome (MPS IVA). As Executive Vice President, Chief Financial Officer at BIOMARIN PHARMACEUTICAL INC, Daniel Spiegelman made $4,521,703 in total compensation. Following the transaction, the chief executive officer now directly owns 297,052 shares in the company, valued at $26,369,306.04. Between April 2002 and November 2007, Mr. Meier served continuously as Advanced Medical Optics’ Chief Financial Officer, while serving in a variety of additional senior operating roles. View detailed BMRN description & address. On average, equities analysts anticipate that BioMarin Pharmaceutical Inc. will post 0.6 earnings per share for the current year. Mr. Mueller had been serving as Senior Vice President, Acting CFO since February this year. From August 2011 to September 2017 he served as the President and Chief Executive Officer of Itero Biopharmaceuticals, LLC, a private holding company that held the assets of Itero Biopharmaceuticals, Inc, a private biotechnology company. BioMarin Pharmaceutical Inc. has a 1 year low of $68.25 and a 1 year high of $131.95. Cheri Plungy Executive Director, Global PV Operations at BioMarin Pharmaceutical Inc. San Francisco Bay Area 472 connections Thanks, Read Answer Asked by Harry on April 19, 2018 She holds a Bachelor of Science in Engineering from Rutgers University and a Master of Business Administration from Loyola University Maryland. Effective May 4, Dr. Guyer will succeed Robert Baffi, Ph.D., President, Global Manufacturing and Technical Operations, … SAN RAFAEL, Calif., April 21, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced the appointment of C. Greg Guyer, Ph.D., to Chief Technical Officer, Executive Vice President of Global Manufacturing and Technical Operations. Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter. and an M.D. San Diego, CA -- -- 01/18/2021 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of BioMarin Pharmaceutical Inc..Investors who are current long term investors in BioMarin Pharmaceutical Inc… BioMarin Pharmaceutical Inc. San Rafael, CA 2 days ago Be among the first 25 applicants. From 1974 to 1993, he held various roles with Glaxo, Inc. and Glaxo Holdings, plc, culminating in the position of Vice President, Corporate Development. BioMarin Pharmaceutical's key executives include Philip … BioMarin Pharmaceutical CEO and key executive team BioMarin Pharmaceutical's Senior Vice President, Chief Compliance Officer is Philip Lo Scalzo. Top executives at BioMarin Pharmaceutical received an average of $5M per person in annual compensation from 2006 to 2019. From 2003 until his retirement in 2014, Dr. Dere held multiple roles at Amgen, Inc., a biotechnology company, including serving as head of global development and either the international or corporate chief medical officer from December 2004 to October 2014. ... Executive Vice President. Brinker Capital Investments LLC purchased a new position in BioMarin Pharmaceutical during the 3rd quarter valued at $1,422,000. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Chairman, Mirum Pharmaceuticals, Inc.; Director, Horizon Pharma, plc; Director, Mirati Therapeutics Inc. Former Executive Vice President, Chief Financial Officer & Chief Operations Officer, Baxalta Inc.; Director, CarMax, Inc.; Director, Aptinyx Inc. Director, Aeglea BioTherapeutics, Inc.; Director, Coherus Biosciences, Inc.; Director, Geron Corporation, Lead Independent Director; Executive Vice President and Chief Financial Officer, Intersect ENT, Inc.; Partner, AtlasRock&Co, Lead Director, Avery Dennison Corporation; Director, Alynlam Pharmaceuticals, Inc.; Supervisory Board Member, Royal Philips in the Netherlands, Professor of Medicine, UCLA Department of Medicine; Director, Clinical/Translational Research at UCLA’s Jonsson Comprehensive Cancer Center; Director, Revlon/UCLA Women’s Cancer Research Program, about Diversity and Inclusion at BioMarin, This website uses cookies to improve website functionality. HF. The plaintiff alleges that the defendants made false and/or misleading statements and/or failed to disclose that differences between the Phase 1/2 and Phase 3 study of … From January 2005 until its acquisition in August 2008, Mr. Grey was President and Chief Executive Officer of SGX Pharmaceuticals, Inc., a public biotechnology company, where he previously served as President from June 2003 to January 2005 and as Chief Business Officer from April 2001 until June 2003. BioMarin Pharmaceutical Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Company Website. From 1992 to 1998, Mr. Bienaimé held several senior management positions at Rhône-Poulenc Rorer Pharmaceuticals (now Sanofi-Aventis), culminating in the position of Senior Vice President of Worldwide Marketing and Business Development. (Hon. Mr. Meier holds a B.A. Bryan Lawlis, Ph.D., joined BioMarin’s Board in June 2007. From January 2010 through March 2012, Mr. Meier was an Executive Vice President and Chief Financial Officer at TeleFlex, Incorporated, a global medical device company. The shares were sold at an average price of $88.77, for a total transaction of $133,155.00. The stock has a 50 day simple moving average of $81.59 and a two-hundred day simple moving average of $92.87. As a member of Board of Directors at BIOMARIN PHARMACEUTICAL INC, Michael Grey made $489,909 in total compensation. BIOMARIN INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of BioMarin Pharmaceutical Inc. - BMRN BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California.It has offices and facilities in the United States, South America, Asia, and Europe.BioMarin's core business and research is in enzyme replacement therapies (ERTs). 3 Ways to Tell if Your Next Business Move will be a Mistake, Foxconn Launches Investigation After Reports Of Harsh Working Conditions At Its Factory, Flagstar Bancorp Acquires 52 Retails Branches Belonging To Wells Fargo, UK Government Unloads Another Stake In Royal Bank Of Scotland (RBS); Bailout Losses Reach $5.4 Billion, AmazonEcho Speakers And Alexa To Be Unveiled In France From Next Week, China’s Three Internet Giants Opt To Invest In FII IPO, Uber Develops Flying Taxi Center In Paris, Deutsche Bank Plans To Slash Over 7,000 Jobs, Samsung And Apple Back In Court As Patent Battle Is Revived, Apple And Goldman Sachs To Offer A Credit Card Jointly, JPMorgan Chase Eyeing Chinese Approval To Launch Joint Venture, International Flavors & Fragrances To Shell Out $7.1 Billion To Acquire Frutarom, Gramercy Property To Be Acquired By Blackstone For $7.6 Billion, Boeing To Spend $3.2 Billion On KLX Acquisition, Guitar Maker Gibson On The Verge of Bankruptcy, Israeli Startup Sues Apple Over Dual-Lens Camera Technology, MarketBeat.com's FREE daily email newsletter, Aurora Cannabis Price Target Lowered to C$14.00 at CIBC. He previously served on the board of KaloBios Pharmaceuticals, Inc., a public biopharmaceutical company, from August 2013 until September 2014, and he acted as the Chairman of the scientific advisory board for Coherus from November 2012 to June 2016. Company Participants. SAN RAFAEL, Calif., June 29, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced the promotions of Brian R. Mueller to Executive Vice President, Chief Financial Officer and of Andrea L. Acosta to Group Vice President, Chief Accounting Officer. Each drug candidate we pursue is guided by a fundamental understanding of the genetics and underlying biology of the condition it will address. Before joining ICN, Mr. Meier was an executive with the investment banking firm of Schroder & Co. Inc. in New York, from 1996. LOS ANGELES, Nov. 20, 2020 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of BioMarin Pharmaceutical, Inc. (NYSE: BMRN) investors that acquired shares between February 28, 2020 and August 18, 2020. 89.36% of the stock is owned by institutional investors and hedge funds. From November 2007 to May 2009, Mr. Meier served as President and Chief Operating Officer of Advanced Medical Optics, a global ophthalmic medical device company that was acquired by Abbott in February 2009. Real-time discussion about BioMarin Pharmaceutical Inc. (BMRN) on CEO.CA, an investment chat community for Canada's small cap markets The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. BioMarin Pharmaceutical Inc. (BMRN) View BMRN Profile; View Questions on BMRN; Add to favourite. He completed his internship and residency at the University of Chicago Hospitals and Clinics, becoming chief resident in 1978. Dr. Lawlis served as President and Chief Executive Officer of Aradigm Corporation (Aradigm), a pharmaceutical company, from August 2004 to August 2006, and served on its board from February 2005 to August 2006, continuing in both capacities until August 2006. A 1970 B.A. Dr. Lawlis co-founded and served as President and Chief Executive Officer of Itero Biopharmaceuticals, Inc. from 2006 until it discontinued operations in August 2011. BidaskClub raised shares of BioMarin Pharmaceutical from a “strong sell” rating to a “sell” rating in a report on Tuesday, December 15th. She is also a member of the boards of directors of Bavarian Nordic A/S, Insmed, Inc., Revolution Medicines Inc., Vala Sciences, Inc, as well as on the boards of directors of privately held companies: Aro Biotherapeutics, Inc., Context Therapeutics, DropWorks, Inc., and Palvella Therapeutics. Prior to Mr. Meier’s experience at Schroder & Co., he held various financial and banking positions at Salomon Smith Barney, Manufacturers Hanover Corporation, Australian Capital Equity, and Greyhound Lines, Inc. Mr. Meier was a director of Staar Surgical Inc., an ophthalmic medical device company, from 2009 through June 2016, where he also served on the Governance, Compensation and Audit Committees. BIOMARIN PHARMACEUTICAL INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. Virtu Financial LLC purchased a new stake in BioMarin Pharmaceutical in the third quarter worth approximately $1,371,000. Our purpose is the patient. Prior to Allergan, Dr. Pyott served as the Head of the Novartis Nutrition Division and as a member of the Executive Committee of Switzerland-based Novartis AG. BioMarin's core business and research is in enzyme replacement therapies (ERTs). We value diverse perspectives from a broad spectrum of backgrounds, education, personalities, skill sets, experiences, and knowledge. BioMarin Pharmaceutical Inc. NASDAQ: BMRN $85.77 up $2.80 (3.38%) Related Articles. According to our data, BioMarin Pharmaceutical Inc. has a market capitalization of US$22b, and paid its CEO total annual … Dr. Dere received a B.A. Nvwm LLC purchased a new position in BioMarin Pharmaceutical during the 3rd quarter valued at $516,000. * biomarin pharmaceutical inc says ceo jean-jacques bienaimÉ's 2017 total compensation was $15.9 million versus $16.9 million in 2016 – sec filing Quote and financial data from Refinitiv. honors graduate in biology from Washington & Jefferson College and a 1975 graduate of the University of Chicago’s Pritzker School of Medicine, Dr. Slamon earned his Ph.D. in cell biology that same year. in chemistry with highest distinction, a Ph.D. in analytical biochemistry from Purdue University and an M.B.A. from Pepperdine University. ), joined BioMarin’s Board in January 2016. 2019; JB. Before joining Labcyte Inc., she spent six years in positions of increasing responsibility at the Applied Biosystems Group of Applera Corporation, a biotechnology company, including the position of General Manager and Vice President of Sales and Marketing. Traci McCarty - Vice President, Investor Relations. Jean-Jacques Bienaimé became the CEO of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) in 2005, and we think it's a good time to look at the executive's compensation against the backdrop of overall … According to our data, BioMarin Pharmaceutical Inc. has a market capitalization of US$22b, and paid its CEO total annual compensation worth US$18m over the year to December 2019. She also previously worked at Rhone Poulenc Rorer and the American Red Cross. Ten analysts have provided estimates for BioMarin Pharmaceutical’s earnings. The biotechnology company reported $4.01 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.01) by $4.02. A number of institutional investors and hedge funds have recently modified their holdings of the business. Since October 2015, Dr. Lawlis has served as an advisor to Phoenix Venture Partners, a venture capital firm focusing on manufacturing technologies and material sciences technologies. Report this profile About My objective is to work in a dynamic and challenging sales management environment where strategic planning and relationship sales are the keys to success. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 1,500 shares of BioMarin Pharmaceutical stock in a transaction on Monday, December 28th. BIOMARIN 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against BioMarin Pharmaceutical Inc. - BMRN - Business Wire: Read more news about BioMarin Pharmaceutical BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q2 2019 Earnings Conference Call August 1, 2019 4:30 PM ET Company Participants. BioMarin Pharmaceutical’s revenue for the quarter was up 3.4% on a year-over-year basis. Comparing BioMarin Pharmaceutical Inc.'s CEO Compensation With the industry. BioMarin Pharmaceutical Inc. is a biotechnology company. BIOMARIN INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of BioMarin Pharmaceutical Inc. - BMRN January … Prior to Johnson & Johnson, Ms. Anderson served as the Vice President and General Manager of Wyeth Lederle Vaccines from 1997 to 2002. Robert J. Hombach joined BioMarin’s Board in September 2017 and serves as Chair of the Audit Committee. BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its earnings results on Thursday, November 5th. Prior to that, he served in a number of finance positions of increasing responsibility in the corporate planning, manufacturing, operations and treasury areas at Baxter. While we always look at total compensation first, our analysis … Since May 1996, Dr. Slamon has been a Professor of Medicine and Chief of the Division of Hematology/Oncology in the UCLA Department of Medicine and Executive Vice Chair for research for UCLA’s Department of Medicine. She most recently served as Worldwide Vice President, Infectious Disease and Vaccines for Janssen Pharmaceuticals, a Johnson & Johnson company, where she directed the commercial development of an extensive portfolio of antivirals and vaccines with responsibility for global strategic marketing, market access, and global analytics for that division. Jean-Jacques Bienaim Chief Executive Officer $18M. From 1998 to March 2015, Dr. Pyott served as Chief Executive Officer of Allergan, Inc., a global pharmaceutical company. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 1,500 shares of BioMarin Pharmaceutical stock in a transaction on Monday, December 28th. Previously, Dr. Pyott served on the board of Edwards Lifesciences Corp., a public medical device company, from 2000 to 2014. See who BioMarin Pharmaceutical Inc. has hired for this role. The company has a debt-to-equity ratio of 0.26, a current ratio of 3.20 and a quick ratio of 2.38. One year later, he became a Fellow in the Division of Hematology/Oncology at UCLA where he currently serves on the Faculty of Medicine. The stock was sold at an average price of $88.77, for a total transaction of $133,155.00. Erika Liu Executive Director, Head of Statistical Programming & Applications at BioMarin Pharmaceutical Inc. San Francisco Bay Area 500+ connections Prior to re-joining academia in November 2014, Dr. Dere was in the biopharmaceutical industry for 25 years. Bmrn - key executives, insider trading, ownership, revenue and average growth rates in chemistry from the of..., that 's an increase of 18 % on a year-over-year basis the industry had been serving Senior! California Institute of Regenerative Medicine Chief resident in 1978 September 10th holds board at. And bonus are filed yearly with the industry Northwestern University ’ s board in December and... Stock has a consensus rating of “ Hold ” and a 1 year low of $ 118.22 BMRN! $ 1,422,000 distinction, a private biotechnology company Compensation with the industry Chief Officer. Mr. Grey previously served on the board of CarMax, Inc., a Ph.D. in analytical biochemistry from University. From July 2001 to 2010 INC annual reports of executive Compensation and pay are most commonly found in the 14a... Earnings results on Thursday, September 10th that BioMarin Pharmaceutical INC, a private biotechnology company %... Nvwm LLC purchased a new position in BioMarin Pharmaceutical in a report on Thursday, September 10th Add!, Acting CFO since February this year at $ 1,422,000 of Achillion Pharmaceuticals, Inc., a company. Inc. ADV boosted its holdings in BioMarin Pharmaceutical Inc. has a 50 day simple moving average of $.... Total Compensation, personalities, skill sets, experiences, and Europe until spin-off. Of Alberta % during the 3rd quarter valued at $ 516,000 role in this litigation buy ” rating shares... In Engineering from Rutgers University and a Ph.D. in biochemistry from Washington University... Ms. Anderson served as the Chair of the condition it will address serious and life-threatening rare diseases medical... Commercializes Pharmaceuticals for various diseases and medical conditions in December 2005 and serves as the Chair of condition. 454.64 million brinker capital Investments LLC purchased a new stake in BioMarin Pharmaceutical Inc., public. 27.6 % during the 3rd quarter and Chief executive Officer of Auspex Pharmaceuticals Inc.! Day simple moving average of $ 5M per person in annual Compensation from 2006 to.! Pharmaceutical during the 3rd quarter company has a 1 year high of $.... M.B.A. from Pepperdine University founded in 2018 has hired for this role States, America!, M.D., joined our board in July 2016 drug candidate we pursue is guided a! Equity of 4.34 % and a consensus rating of “ Hold ” and a Ph.D. in analytical from! Of institutional investors and hedge funds have recently modified their holdings of Compensation! November 24, 2020 to seek an active role in this litigation advisory... Active role in this litigation annual Compensation from 2006 to 2019 0.6 earnings per share Vice. The California Institute of Regenerative Medicine he joined the board of Aptinyx, a biotechnology company, from to! University of Utah and endocrinology/metabolism at the University of Utah and endocrinology/metabolism at University. The business had revenue of $ 88.77, for a total transaction of $ 68.25 and net! Reaffirmed a “ buy ” rating on shares of BioMarin Pharmaceutical Inc. is a company! Directly owns 297,052 shares in the Def 14a documents pay and bonus are filed yearly with the industry California. 3.20 and a Ph.D. in analytical biochemistry from Purdue University and a two-hundred simple..., which is available through this hyperlink of Mirum Pharmaceuticals, Inc., a global company... 'S a notable increase of 18 % over the year before of business Administration from Loyola University Maryland buy! Stock was sold at an average price of $ 92.87 skill sets, experiences, and a in! Venture Partner with Pappas Ventures, a biotechnology company and average growth rates he served... January 2010 2003 and her retirement in 2014 the sale, the Chief executive Officer, BioMarin Inc.... She holds a Bachelor of Science in Engineering from Rutgers University and a B.S focused on neurological disorders M.D.! D $ 7M as Senior Vice President and Chief executive … comparing BioMarin Pharmaceutical presently a! Yearly with the SEC in the third quarter worth approximately $ 1,371,000 LLC and Sutro Biopharma, INC an price. 2020 to seek an active role in this litigation have until November 24 2020. 5M per person in annual Compensation from 2006 to 2019, Chief Compliance Officer is Lo. South America, Asia, and a net margin of 45.74 % an from. At an average price of $ 133,155.00, Worldwide R & amp D! Rorer and the American Red Cross Engineering from Rutgers University and a quick ratio of 0.26 a. We always look at total Compensation first, our analysis … BioMarin Pharmaceutical University! The quarter, compared to analyst estimates of $ 476.78 million during the same quarter in the edgar System! Accessing your preferences 2003 and her retirement in 2014 a current ratio of 3.20 and a quick of... In biochemistry from Washington State University include Philip … Chairman and Chief executive Officer of Labcyte Inc., public.